Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 115 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Continuous ART Clear all
Terminated Not applicable Interventional

Effects of Repeated Memory Training on Memory Function and Addiction Related Processes

NCT03285256
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Experimental memory training, Comparator memory training 1, Comparator memory training 2
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

NCT03639311
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, RPV LA, RPV, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 24, 2026, 7:13 PM EDT
Withdrawn Phase 2 Interventional

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

NCT05582694
View directory record Official record
Conditions
Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection
Interventions
UB-421
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Positive Steps to Enhance Problem Solving Skills

NCT03092531
View directory record Official record
Conditions
Adherence
Interventions
Positive STEPS
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
16 Years to 29 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 24, 2026, 7:13 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

NCT03299049
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
1,049 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Not applicable Interventional Results available

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

NCT02251236
View directory record Official record
Conditions
HIV
Interventions
Stribild, Genvoya
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Phase 2 Interventional Results available

Raltegravir Therapy for Women With HIV and Fat Accumulation

NCT00656175
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
raltegravir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 24, 2026, 7:13 PM EDT
Enrolling by invitation Not applicable Interventional

Auditory Stimulation Effects on Sleep and Memory in Patients With Epilepsy

NCT04788628
View directory record Official record
Conditions
Epilepsy
Interventions
Baseline, Motor procedural memory task, Motor procedural memory task plus auditory stimulation
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

NCT02105987
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
ABC/DTG/3TC FDC, Ongoing cART regimen
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
87
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 24, 2026, 7:13 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Impact of Metformin on Immuno-virologic Parameters in HIV

NCT04500678
View directory record Official record
Conditions
HIV/AIDS
Interventions
Metformin
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
40 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Phase 4 Interventional Results available

Menopur Mixed Protocol

NCT01417195
View directory record Official record
Conditions
Infertility
Interventions
Bravelle, Menopur
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Lone Tree, Colorado • Clearwater, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Not applicable Interventional

Music in the Emergency Department (ED)

NCT03047915
View directory record Official record
Conditions
Anxiety
Interventions
Music
Other
Lead sponsor
Columbia University
Other
Eligibility
65 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tertulias Social Isolation Women's Groups Study

NCT04254198
View directory record Official record
Conditions
Social Isolation, Depression
Interventions
TERTULIAS structured dialogue peer support groups, Modified Attention Placebo Control (MAPC)
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Phase 2 Interventional

Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma

NCT00003575
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, recombinant interleukin-12, etoposide, ifosfamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Development and Effectiveness of Museum-Based Experiences for Individuals With Chronic Pain

NCT04091893
View directory record Official record
Conditions
Chronic Pain
Interventions
Usual care/wait list, Art Rx, Artful Meditation
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 24, 2026, 7:13 PM EDT
Not listed Not applicable Interventional

Unobtrusive Sensing of Medication Intake ("USE-MI")

NCT03571022
View directory record Official record
Conditions
Medication Adherence
Interventions
USE-MI System
Behavioral
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Not applicable Interventional Results available

Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01

NCT03844269
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AKL-T01
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Rafael, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 24, 2026, 7:13 PM EDT
Terminated Phase 1 Interventional Results available

Pharmacokinetics and Safety of SAR441236

NCT03705169
View directory record Official record
Conditions
HIV-1-infection
Interventions
SAR441236, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Phase 3 Interventional Results available

Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures

NCT03565211
View directory record Official record
Conditions
Progesterone Supplementation in Women Undergoing ART
Interventions
Progesterone vaginal ring
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
15
States / cities
Tempe, Arizona • Encino, California • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Not applicable Interventional Results available

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

NCT00672932
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2013 · Synced Oct 24, 2026, 7:13 PM EDT
Completed Phase 4 Interventional Results available

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

NCT00145795
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Current Dual NRTI Backbone, Current Regimen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 24, 2026, 7:13 PM EDT
Completed No phase listed Observational Results available

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

NCT05510908
View directory record Official record
Conditions
HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
Interventions
Non-Interventional, Non-Interventional Follow-up
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
La Jolla, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 7:13 PM EDT
Recruiting No phase listed Observational

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

NCT04979728
View directory record Official record
Conditions
HIV Treatment, HIV Prevention
Interventions
At Home Self-Collections
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 24, 2026, 7:13 PM EDT